In fact, in this study CD133 expression was observed in 31% of ovarian cancer samples; CD133 expression was associated with high-grade serous carcinoma, late-stage disease, ascites level and absence of response to therapy [266] Furthermore, CD133 expression was associated with shorter overall survival time [266]. This evidence concerns the gene PROM1 and ovarian carcinoma.